News & Updates
Poster on GNUV205 presented at the Immuno-Oncology Summit GNUV205 demonstrates Genuv’s “no-alpha/attenuated beta fused with anti-PD-1” strategy to reduce toxicity Excerpt from the Press Release: SEOUL, Republic of Korea & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immuno-oncology therapeutics, unveiled a…
Read More
• No safety concerns noted in ongoing clinical trial• Study timeline remains on track Excerpt from the Press Release: MALVERN, Pa., Oct. 12, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the…
Read More
Meet in person with Christopher Kata during CPHI in Frankfurt, on November 1st to 3rd. If you’re attending be sure to reach out to Christopher to schedule a one on meeting! Each year CPHI unites more than 100,000 pharmaceutical professionals through exhibitions, conferences and online communities to network, identify business opportunities and expand the global…
Read More
Excerpt from the Press Release: MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has initiated DAZALS –…
Read More
– Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome (ALGS) – Characterization of four-year growth improvement in Alagille syndrome with maralixibat – New analysis evaluating health-related quality of life impact assessed on caregivers of children with Alagille syndrome – Mirum to host a scientific symposium on the…
Read More
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples Increase in the ratio of glycosylated αDG to total αDG from baseline towards normal levels, suggesting that the investigational oral therapy, BBP-418, has the potential to address the root cause of LGMD2i Large, sustained reduction…
Read More
Christopher Kata is once again attending the CRAC – Future Considerations for Conducting Clinical Trials November 17th at the Markland Wood Golf Club. If you’re attending be sure to reach out to Christopher to schedule a one on meeting or search him out at the meeting! Christopher will be delivering a presentation titled “How To…
Read More
Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors. Biomea Fusion will now initiate a Phase I/Ib clinical trial (COVALENT-102) of BMF-219 as a monotherapy in patients who have unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC) or pancreatic…
Read More
Single ascending doses to be evaluated in healthy volunteers in Q4 2022 Single ascending doses to be evaluated in subjects with chronic hepatitis B beginning in Q1 2023 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on…
Read More AtomVie Global Radiopharma is the latest company launched by the OICR-supported centre Excerpt from the Press Release: The Centre for Probe Development and Commercialization’s (CPDC) newest spinout company has now launched as AtomVie Global Radiopharma Inc. On August 24, the Hamilton-based radiopharmaceutical company announced it had closed Series A financing with healthcare investment firm Avego…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?